IMPACT OF ANTIFIBROTIC USE ON HEALTHCARE RESOURCE USE AND COST IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) IN A COMMERCIALLY INSURED PATIENT POPULATION

被引：1
|
作者：
Corral, Mitra
Deyoung, Kathryn
Kong, Amanda
机构：
来源：
CHEST | 2019年 / 156卷 / 04期
关键词：
D O I：
10.1016/j.chest.2019.08.1038
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1137A / 1137A
页数：1
相关论文
共 50 条
  • [11] MAINTAINING PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) ON ANTIFIBROTIC THERAPY; THE NURSES' CHALLENGE
    Burge, G. A.
    Alldrick, H.
    Briggs, E.
    Neighbour, K.
    Burge, P. S.
    Walters, G. I.
    THORAX, 2017, 72 : A167 - A168
  • [12] SUBOPTIMAL DOSING AND DISCONTINUATION OF ANTIFIBROTIC AGENTS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Pimple, P.
    Nathan, S. D.
    Swigris, J. J.
    Olson, A. L.
    Shetty, S.
    VALUE IN HEALTH, 2024, 27 (06) : S314 - S314
  • [13] Outcomes of Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis (IPF) Patients with Circulating Autoantibodies
    Smith, A.
    Ding, G.
    Kropski, J.
    Mason, W.
    Lancaster, L. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [14] Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
    Wuyts, Wim A.
    Dahlqvist, Caroline
    Slabbynck, Hans
    Schlesser, Marc
    Gusbin, Natacha
    Compere, Christophe
    Maddens, Sofie
    Rizzo, Shemra
    Kirchgaessler, Klaus-Uwe
    Bartley, Karen
    Bondue, Benjamin
    PULMONARY THERAPY, 2022, 8 (02) : 181 - 194
  • [15] Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
    Wim A. Wuyts
    Caroline Dahlqvist
    Hans Slabbynck
    Marc Schlesser
    Natacha Gusbin
    Christophe Compere
    Sofie Maddens
    Shemra Rizzo
    Klaus-Uwe Kirchgaessler
    Karen Bartley
    Benjamin Bondue
    Pulmonary Therapy, 2022, 8 : 181 - 194
  • [16] The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea
    Kim, Yong Hyun
    Myong, Jun Pyo
    Kwon, Soon Seog
    Park, Kihoon
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [17] Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
    Hrishikesh P. Kale
    Zaina P. Qureshi
    Ruchit Shah
    Rezaul Khandker
    Marc Botteman
    Weilin Meng
    Ruth Benca
    Advances in Therapy, 2021, 38 : 5221 - 5237
  • [18] Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
    Kale, Hrishikesh P.
    Qureshi, Zaina P.
    Shah, Ruchit
    Khandker, Rezaul
    Botteman, Marc
    Meng, Weilin
    Benca, Ruth
    ADVANCES IN THERAPY, 2021, 38 (10) : 5221 - 5237
  • [19] THE IMPACT OF HIGH RISK AND CHRONIC OPOID USE AMONG COMMERCIALLY INSURED ENDOMETRIOSIS PATIENTS ON HEALTHCARE RESOURCE USE AND COSTS IN THE UNITED STATES
    Estes, S.
    Soliman, A. M.
    Zivkovic, M.
    Zhu, X.
    Chopra, D.
    VALUE IN HEALTH, 2020, 23 : S239 - S239
  • [20] Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
    Bonniaud, Philippe
    Cottin, Vincent
    Spagnolo, Paolo
    Nolin, Maeva
    Dalon, Faustine
    Kirchgassler, Klaus-Uwe
    Chia, Jenny
    Kamath, Tripthi
    Van Ganse, Eric
    Belhassen, Manon
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
12345